Core Insights - LeMaitre Vascular, Inc. reported strong Q3 2025 results, driven by significant sales growth in grafts and shunts, and announced a quarterly dividend of $0.20 per share [1][5][3] Financial Performance - Q3 2025 sales reached $61.0 million, representing an 11% increase year-over-year, with organic growth of 12% [8][22] - Adjusted gross margin improved to 70.8%, up from 67.8% in Q3 2024, attributed to higher average selling prices and manufacturing efficiencies [3][8] - Adjusted operating income was $16.9 million, a 29% increase, benefiting from moderating operating expenses [3][8] - Net income for Q3 2025 was $17.4 million, compared to $11.1 million in Q3 2024, reflecting a 56% increase [20][21] Sales Growth Drivers - Grafts and shunts were key contributors to sales growth, with grafts increasing by 23% and shunts by 18% [3] - Artegraft experienced accelerated growth of 33% due to its international launch [3] - Sales in the EMEA region increased by 18%, the Americas by 10%, and APAC by 4% [3] Business Outlook - For Q4 2025, the company expects sales between $61.8 million and $63.8 million, with full-year guidance set at $247 million to $249 million, both reflecting a 13% increase [4] - Gross margin is projected at 71.2% for Q4 and 71.4% for the full year [4] - Adjusted EPS for Q4 is expected to be between $0.64 and $0.69, with full-year guidance of $2.48 to $2.53, indicating a 30% increase [4] Dividend and Share Repurchase - The Board of Directors approved a quarterly dividend of $0.20 per share, payable on December 4, 2025 [5] - A share repurchase program was authorized for up to $75 million, set to conclude on February 17, 2026, unless extended [6] Company Overview - LeMaitre Vascular specializes in vascular devices, implants, and services for treating peripheral vascular disease, a condition affecting over 200 million people globally [11]